"T-Lymphocytes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
| Descriptor ID |
D013601
|
| MeSH Number(s) |
A11.118.637.555.567.569 A15.145.229.637.555.567.569 A15.382.490.555.567.569
|
| Concept/Terms |
T-Lymphocytes- T-Lymphocytes
- T Lymphocytes
- T-Lymphocyte
- T-Cells
- T Cells
- T-Cell
- Thymus-Dependent Lymphocytes
- Lymphocyte, Thymus-Dependent
- Lymphocytes, Thymus-Dependent
- Thymus Dependent Lymphocytes
- Thymus-Dependent Lymphocyte
|
Below are MeSH descriptors whose meaning is more general than "T-Lymphocytes".
Below are MeSH descriptors whose meaning is more specific than "T-Lymphocytes".
This graph shows the total number of publications written about "T-Lymphocytes" by people in this website by year, and whether "T-Lymphocytes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 2 | 4 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2015 | 2 | 1 | 3 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 4 | 0 | 4 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 5 | 7 |
| 2025 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "T-Lymphocytes" by people in Profiles.
-
Antigen-presenting fibroblasts: emerging players in immune modulation and therapeutic targets. Theranostics. 2025; 15(8):3332-3344.
-
Molecular dynamics at immune synapse lipid rafts influence the cytolytic behavior of CAR T cells. Sci Adv. 2025 Jan 10; 11(2):eadq8114.
-
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025 Jan; 637(8047):940-946.
-
2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus. Signal Transduct Target Ther. 2024 Nov 17; 9(1):323.
-
Engraftment of a surrogate antigen onto tumor cell surface via pHLIP peptide to universally target CAR-T cell therapy to solid tumors. Cancer Lett. 2025 Jan 01; 608:217319.
-
Tumour evolution and microenvironment interactions in 2D and 3D space. Nature. 2024 Oct; 634(8036):1178-1186.
-
MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors. J Immunother Cancer. 2024 Sep 23; 12(9).
-
Editorial: Quantification and prediction of T-cell cross-reactivity through experimental and computational methods. Front Immunol. 2024; 15:1377259.
-
Decoding the mechanisms of chimeric antigen receptor (CAR) T cell-mediated killing of tumors: insights from granzyme and Fas inhibition. Cell Death Dis. 2024 02 02; 15(2):109.
-
CrossDome: an interactive R package to predict cross-reactivity risk using immunopeptidomics databases. Front Immunol. 2023; 14:1142573.